Psychedelic Bulletin #200: Czechia psilocybin access prospects, atai-Bekley Psytech deal watch, and Q1 2025 lobbying update

Psilocybin policy in Czechia takes center stage as the Chamber of Deputies votes to advance reforms to the criminal code, including an amendment that would legalize psilocybin as a medicine in limited therapeutic contexts under strict supervision. The amendment outlines administration in psychiatric hospitals and affiliated facilities by qualified professionals, requires session monitoring and long-term record keeping, and signals that key details will be set later through government regulations (such as conditions, quantity limits, and required competencies). The bill then moves to the Senate, with commentary emphasizing that even broad political support does not guarantee timely patient access. The broader bulletin also frames access expectations by comparing Czechia’s proposed pathway with real-world results from Australia, Switzerland, and Canada, highlighting that early patient uptake has often been limited by infrastructure, therapist availability, and regulatory design. The issue further tracks psychedelic industry and political dynamics, including a closer look at atai’s potential acquisition of Beckley Psytech and a Q1 2025 update on psychedelic lobbying spend by drug developers and nonprofits.